mRNA Vaccines to Prevent COVID-19 Disease and Reported Allergic Reactions: Current Evidence and Suggested Approach

The U.S. Food and Drug Administration (FDA) has recently issued an Emergency Use Authorization (EUA) for 2 highly effective coronavirus disease 2019 (COVID-19) vaccines from Pfizer-BioNTech and Moderna. This has brought hope to millions of Americans in the midst of an ongoing global pandemic. The FD...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The journal of allergy and clinical immunology in practice (Cambridge, MA) MA), 2021-04, Vol.9 (4), p.1423-1437
Hauptverfasser:	Banerji, Aleena, Wickner, Paige G., Saff, Rebecca, Stone, Cosby A., Robinson, Lacey B., Long, Aidan A., Wolfson, Anna R., Williams, Paul, Khan, David A., Phillips, Elizabeth, Blumenthal, Kimberly G.
Format:	Artikel
Sprache:	eng
Schlagworte:	Allergic reactions Allergies Allergy Anaphylaxis Anaphylaxis - chemically induced Clinical trials Clinical Trials, Phase III as Topic Coronaviruses COVID-19 COVID-19 - prevention & control COVID-19 vaccines COVID-19 Vaccines - adverse effects Disease control Drug dosages Epidemiology Fatalities Food allergies Guidelines Humans Minority & ethnic groups mRNA mRNA Vaccines Pandemics Polyethylene glycol Polysorbate Public health Regulatory agencies Regulatory approval Risk stratification United States United States Food and Drug Administration Vaccine Vaccines Vaccines, Synthetic - adverse effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!